Perth Blood Institute was proud to contribute to the global conversation on the future of multiple myeloma treatment through the presentation of the AQUILA study at the 12th World Congress on Controversies in Multiple Myeloma in Paris.

The congress brought together leading international experts in hematology and oncology to debate emerging evidence, challenge existing treatment paradigms, and explore innovative approaches to patient care.

The AQUILA presentation highlighted the ongoing commitment of the research community to improving outcomes for people living with smouldering multiple myeloma through earlier intervention strategies and advancing clinical research.

As a contributor to the AQUILA study, PBI is pleased to support collaborative research that is helping shape new approaches to treatment and care for people affected by smouldering multiple myeloma.

Events such as COMy play an important role in fostering international collaboration and accelerating progress in blood cancer research and innovation.